ABL106 / ABL Bio - LARVOL DELTA

A humanized anti-b7h3×4-1BB bispecific antibody exerts potent antitumour effects through the activation of innate and adaptive immunity. (PubMed, Biochem Biophys Res Commun) - "In addition, HK056-001 has no significant liver toxicity in human 4-1BB-KI BALB/c mice bearing CT26-B7H3 tumors. The optimal anti-B7H3 × 4-1BB bsAb HK056-001 exhibited synergistic antitumour effects by inducing an ADCC effect (innate immunity) and activating the 4-1BB signaling pathway (adaptive immunity) upon cross-bridging with B7H3 with no obvious toxicity, which could potentially provide a better therapeutic window compared to what is seen with 4-1BB agonists."

Journal • Hepatology • Oncology • CD276

A novel B7H3×4–1BB bispecific antibody for solid tumor treatment (SITC 2023) - "Conclusions HK056–001, a B7H3×4–1BB bsAb with human IgG1 Fc fragment prevents tumor development by killing tumor cells directly via effector functions mediated by NK and cytotoxic T cells. These results indicate that this bsAb holds the potential to be developed as a novel clinical therapy for cancer types with B7H3 expression."

IO biomarker • Oncology • Solid Tumor • CD276 • IFNG • TNFRSF9